Draupnir Bio

About Draupnir Bio

Draupnir Bio is a biotechnology company focused on pioneering the next frontier of extracellular protein degradation. They harness the natural machinery of the lysosome to develop oral, small molecule degraders targeting extracellular pathogenic proteins, aiming to revolutionize targeted protein degradation (TPD). Led by an experienced team and backed by leading European investors, they use a proprietary technology platform targeting lysosome receptors.

Products & Services

Oral Small Molecule Degraders:Innovative therapies targeting extracellular and membrane-bound proteins using a novel technology platform for lysosome receptor targeting.

Specialties

Targeted Protein Degradation (TPD) Extracellular Protein Degradation Lysosome Receptor Targeting Small Molecule Degraders

Funding History

Debug: View Raw Funding Data

#	Type	Amount Fields	Date Fields	Investors
1	RT: Seed T: - FT: Seed	A: 12000000 MR: - FA: €12 million FAN: 12000000	D: 2024-07-17 FD: 2024-07-17	5 investors

Seed Latest

2024-07-17

$12.0M

5 investors (Pro only)

Growth Metrics

+45%

Employee Growth

YoY

3.2x

Funding Growth

Last Round

12

Markets

Operating

10K+

Customers

Active

View 3 more growth metrics with Pro

Unlock All Metrics

Mock Up

Team & Leadership

A

Andrew Hotchkiss

Chief Executive Officer

C

Casper Tind Hansen

Chief Business Officer

C

Camilla Gustafsen

Co-Founder and VP Biology

S

Simon Glerup

Co-Founder and Chief Scientific Officer

E

Eva-Lotta Allan

Chair of the Board

I

Ivan Burkov

Junior Partner at Inkef

View 8 more team members with Pro

Unlock Full Team Directory

Recent News

Draupnir Bio Announces New Product Launch

2 days ago

Company unveils innovative solution to transform the industry, expanding market reach and capabilities...

Leadership Team Expands with Industry Veteran

1 week ago

New executive brings 20+ years of experience to accelerate growth and strategic initiatives...

Company Recognized as Industry Leader

2 weeks ago

Receives prestigious award for innovation and customer satisfaction in competitive market...

Key Competitors

C1

Competitor Alpha

Series B · $50M raised

C2

Competitor Beta

Series C · $120M raised

C3

Competitor Gamma

Series A · $25M raised

C4

Competitor Delta

Seed · $10M raised